Key regions: Germany, United States, France, China, Canada
The demand for Anti-Hypertensive Drugs in Southern Europe has been steadily increasing in recent years.
Customer preferences: Patients in Southern Europe have shown a preference for combination therapies that include multiple classes of anti-hypertensive drugs. This is due to the fact that many patients in the region have multiple comorbidities, such as diabetes and high cholesterol, which require a more comprehensive treatment plan. Additionally, patients in Southern Europe are increasingly interested in natural and alternative treatments for hypertension, which has led to a rise in demand for herbal remedies and supplements.
Trends in the market: Spain and Italy are the largest markets for anti-hypertensive drugs in Southern Europe. Both countries have experienced steady growth in demand for these drugs due to an aging population and an increase in the prevalence of hypertension. In Spain, the market for anti-hypertensive drugs is also being driven by the country's universal healthcare system, which provides free or low-cost access to these medications. In Italy, the market is being driven by the country's high rate of cardiovascular disease.
Local special circumstances: In Greece, the economic crisis of the past decade has had a significant impact on the market for anti-hypertensive drugs. Many patients have been unable to afford their medications, which has led to a decrease in demand. However, the market is expected to recover as the country's economy improves. In Portugal, the market for anti-hypertensive drugs is being driven by the country's high rate of obesity, which is a major risk factor for hypertension.
Underlying macroeconomic factors: The demand for anti-hypertensive drugs in Southern Europe is being driven by several underlying macroeconomic factors. These include an aging population, an increase in the prevalence of hypertension, and a rise in healthcare spending. Additionally, the region's high rate of cardiovascular disease is contributing to the growth of the market. However, economic factors, such as the recent recession in Greece, have had a negative impact on the market. Overall, the market for anti-hypertensive drugs in Southern Europe is expected to continue growing in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
